Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

EU approves Roche’s Cotellic in combo therapy against skin cancer

The European Union gave its green light to Roche’s Cotellic for use in combination with the drug Zelboraf against advanced melanoma, the company said on Wednesday.   Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015. It has been […]

Read More »

Pfizer’s Lyrica shows no relief from post-traumatic nerve pain

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday. Currently, there is no approved treatment in the United […]

Read More »

Why Price Gouging May Come to an End

(And a way to save some drug companies from themselves) November 25, 2015 By Karl Thiel for BioSpace.com   Price gouging in the pharmaceutical industry has been much in the news lately. There was, of course, the recent case of Turing Pharma and its 5,400 percent increase on the price on Daraprim, a decades-old drug. […]

Read More »

Research raises questions over ADHD drug effects

Researchers voiced concern on Wednesday about poor quality studies on the popular ADHD treatment Ritalin, saying evidence of some benefits, but also of sleep problems and appetite loss, suggests the drug should be prescribed with caution. Ritalin is sold by Swiss pharmaceutical firm Novartis NOVN.VX, known generically as methylphenidate and also sold under the brand […]

Read More »

FDA rejects Indivior’s nasal spray for opioid overdose

Indivior Plc said on Tuesday the U.S. Food and Drug Administration rejected its nasal spray for the emergency treatment of opioid overdose. The company said it was reviewing the health regulator’s response. These sprays contain naloxone, a drug that has been used to treat opioid overdose for nearly 45 years in injectable forms. Last week, […]

Read More »

FDA approves expanded use of Bristol-Myers’ skin cancer drug

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer. Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30. The drug has been approved for […]

Read More »

Novartis heart failure medicine Entresto wins EU approval

The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.   Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate […]

Read More »

Docs, and patients, should remember to use generics

(Reuters Health) – Prescribing generic medicines instead of brand name drugs whenever possible cuts costs, improves patient adherence and improves health outcomes, according to a new recommendation from the American College of Physicians. “Generic medications are cheaper and patients are more likely to get those prescriptions filled,” said Dr. Amir Qaseem of the American College […]

Read More »

Bristol-Myers signs deal with U.N. group for generic hepatitis C drug

A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co to allow generic versions of the company’s hepatitis C drug to be sold in 112 low- and middle-income countries. The drug, Daklinza, is on the World Health Organization’s list of essential medicines. Hepatitis […]

Read More »

Novartis AG Fesses Up to Valeant-Like Pharmacy Scheme in $390 Million Settlement

BASEL, Switzerland – Novartis AG (NVS) will pay $390 million to settle a civil lawsuit related to the kickback payments to specialty pharmacy companies that distributed the drugs Exjade and Myfortic, Novartis announced Friday. The settlement, which is between Novartis Pharmaceutical Corporation (NVS), a U.S. subsidiary of Novartis AG, will be paid to both the […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom